Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 56
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03882281 | Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia | ||
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | ||
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | ||
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. | ||
| NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | ||
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | ||
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | ||
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | ||
| NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | ||
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | ||
| NCT03537482 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | ||
| NCT05517616 | The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects | ||
| NCT02935907 | APG-115 in Patients With Advanced Solid Tumors or Lymphomas | ||
| NCT03883100 | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation | ||
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | ||
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | ||
| NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | ||
| NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | ||
| NCT03883087 | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation | ||
| NCT06641414 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). | ||
| NCT04001777 | A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | ||
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | ||
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CP-CML | ||
| NCT06319456 | A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | ||
| NCT04893759 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | ||
| NCT04354727 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | ||
| NCT07282093 | Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment | ||
| NCT03080311 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | ||
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | ||
| NCT04568265 | A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B | ||
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | ||
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | ||
| NCT04126707 | The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans | ||
| NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | ||
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | ||
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | ||
| NCT05594758 | Named Patient Program for Olverembatinib (HQP1351) | ||
| NCT06401603 | A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | ||
| NCT03386526 | APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies | ||
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | ||
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | ||
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | ||
| NCT03585322 | APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B | ||
| NCT04501120 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML | ||
| NCT05773586 | A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients | ||
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | ||
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | ||
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | ||
| NCT06182969 | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | ||
| NCT06817720 | Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase |
